Enthera
  • About Us
    • At a Glance
    • Management Team
    • Board of Directors
    • Advisors
    • Investors
    • Organization and management
  • Our Science
  • Pipeline
  • Collaborations
  • Media Centre
    • Press Releases
    • Events
    • Publications
    • Interactive Media
    • In The News
  • Careers
  • Contact Us
  • Menu Menu
  • LinkedIn
WATCH FULL VIDEO

First-in-class therapeutics for autoimmune disorders

Developing the first disease-modifying treatment for severe autoimmune disorders.

Learn more

About Us

We develop first-in-class biologics for several underserved autoimmune conditions. Our therapeutic approach aims to preserve and re-establish organ cell function, transforming the treatment paradigm for intractable autoimmune diseases.

Learn more

Pathway

We target the IGFBP3/TMEM219 axis, a novel pathway involved in cell apoptosis in the gut, pancreas and other organs which plays a key role in the development of Type 1 Diabetes and Inflammatory Bowel Disease.

Learn more

Pipeline

Our discovery engine delivers libraries of monoclonal antibodies (mAbs) and fusion proteins that target the IGFBP3/TMEM219 pathway. Our lead program Ent001 is expected to enter Phase I clinical trials by 2021.

Learn more

News feed

Will work as home page

Latest News
4th May 2022

Enthera Pharmaceuticals nomina Aled Williams come amministratore delegato

4th May 2022

Enthera Pharmaceuticals Appoints Aled Williams as Chief Executive Officer

Circulating hormones control gut stem cell in diabetes (Featuring Paolo Fiorina, Enthera’s CSO)

View more media

linkedin
© Enthera. All rights reserved
Enthera Srl, Via Gioberti, 8, 20123 Milano, Italy
T: +39 02 49533580
E: info@entherapharmaceuticals.com
  • Privacy Policy
  • Corporate Documents
Website by Instinctif Partners
Scroll to top